On the other hand, several researchers have reported that TGFβ increases sensitivity to cisplatin for cancer treatment (Thavaraj et al, 2005; Irigoyen et al, 2010) and therefore, SMURF2 will be available as a biomarker for identification of responders for FOLFOX therapy. Here, SMURF2 is linked to cancer.